Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fragmin dosing optimization in hemodialysis (PARROT)
NCT01879618Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dalteparin in thrombosis, sponsored by Pfizer. Primary endpoint: Mean Percent of Successful HD Sessions. Started Oct 2013; status: completed.
02
Drugs
dalteparin
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT01879618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01879618.